title: [Evidence and utility of etidronate for the treatment of osteoporosis].
abstract: Etidronate is the first bisphosphonate for the treatment of osteoporosis in Japan. Etidronate is useful for the treatment of postmenopausal osteoporosis, glucocorticoid induced osteoporosis, osteoporosis in men, and disused osteoporosis. Etidronate is less effective than other bisphosphonate, such as alendronate and risedronate, in reduction of fracture risk especially non-vertebral fracture, although bone mineral density in femoral neck is significantly increased.
authors.affiliation: Kitago Orthopaedic Clinic/Sapporo Medical University, Department of Orthopaedic Surgey.
authors.forename: Junichi
authors.initials: J
authors.lastname: Takada
authors.forename: Kousuke
authors.initials: K
authors.lastname: Iba
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Yamashita
authors.forename: Takashi
authors.initials: T
authors.lastname: Yoshizaki
mesh_terms: D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D012968:Etidronic Acid / Q000008:administration & dosage*; D019317:Evidence-Based Medicine; D005260:Female; D005272:Femur Neck / Q000378:metabolism; D006801:Humans; D008159:Lumbar Vertebrae / Q000378:metabolism; D008297:Male; D015201:Meta-Analysis as Topic; D010024:Osteoporosis / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D012306:Risk; D016103:Spinal Fractures / Q000209:etiology / Q000517:prevention & control
chemical_list: D050071:Bone Density Conservation Agents; D012968:Etidronic Acid